Was 2025 over-inflated? Wolfe downgraded Enterprise Products Partners (EPD.US) to "underperform" - valuation is too high and advantages are no longer present.
Wolfe Research published a research report, downgrading midstream energy company Enterprise Products Partners from "in line with peers" to "underperforming peers," while giving a target price of $31.
Wolfe Research released a research report, downgrading the rating of midstream energy company Enterprise Products Partners (EPD.US) from "in line with industry" to "underperform," while setting a target price of $31. Wolfe pointed out that the company's performance in 2025 was very weak, but the stock price has shown a strong rally, leading to its current valuation being significantly higher than industry peers.
Analyst Keith Stanley believes that Enterprise Products no longer has the confidence to enjoy a premium valuation over midstream energy Master Limited Partnerships (MLPs) in the industry. The reasons being, the company's performance in 2025 confirmed that its business defensiveness is not outstanding; its current balance sheet situation is in line with most industry peers, and its previous competitive advantage has been greatly weakened; its core Permian Basin natural gas liquids growth business is facing intense market competition, with the risk of industry oversupply increasing.
Stanley also stated that he is cautiously optimistic about the eventual recovery of the oil market in 2026, as well as the alleviation of transportation bottlenecks for natural gas in the Permian Basin these two trends would benefit stocks related to the Permian Basin. However, he emphasized that after the significant stock price increase in 2025, Enterprise Products' stock price has much less room to grow compared to its industry peers. Additionally, considering the company's historically conservative capital allocation strategy, the long-awaited stock buyback program may disappoint investors in the end.
Related Articles

HK Stock Market Move | QINGSONG HEALTH (02661) rose more than 14% to a record high. Since its listing, the stock price has increased by 40%. Recently, the evidence-based medical intelligent body "Zheng Yuanfang" was released.

HK Stock Market Move | CHENMING PAPER(01812) rose nearly 8% again, with multiple bases operating normally. The company is pursuing a strategy of divesting non-core businesses.

CICC International: Advanced driver assistance systems are expected to open up independent growth paths in 2026. Third-party and cost-effective enterprises are expected to benefit from it.
HK Stock Market Move | QINGSONG HEALTH (02661) rose more than 14% to a record high. Since its listing, the stock price has increased by 40%. Recently, the evidence-based medical intelligent body "Zheng Yuanfang" was released.

HK Stock Market Move | CHENMING PAPER(01812) rose nearly 8% again, with multiple bases operating normally. The company is pursuing a strategy of divesting non-core businesses.

CICC International: Advanced driver assistance systems are expected to open up independent growth paths in 2026. Third-party and cost-effective enterprises are expected to benefit from it.

RECOMMEND

“A+H” Team Continues To Expand Hard Technology Firms Accelerate Global Deployment
11/03/2026

Anti‑Stagflation Theme Guides Hong Kong Allocation Institutions Identify Power And Energy Assets As Short‑Term Core
11/03/2026

U.S. Equities Enter “Always‑On” Trading Era Nasdaq Advances Stock Tokenization Framework
11/03/2026


